- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02500927
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
October 22, 2018 updated by: Astellas Pharma Inc
Phase II Study of ASP8273 - An Open-Label, Study of the Oral Administration of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-NaïvePatients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
The purpose of this study is to determine the safety, the antitumor activity and the pharmacokinetics of ASP8273 in EGFR tyrosine kinase inhibitor (EGFR-TKI)-naïve patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
This study consists of a single-dose period (Cycle 0 lasting 3 days) and a multiple-dose period (from Cycle 1 onwards, each cycle lasting 21 days).
To compare the PK between ASP8273 Capsules and ASP8273 Capsules A, enrolled subjects will receive a single oral dose of ASP8273 Capsules A on Day 1 of Cycle 0 in the single-dose period and will then be observed for 3 days (including the day of dosing).
In the multiple-dose period, subjects will receive multiple oral doses of ASP8273 Capsules during each cycle lasting 21 days.
From the viewpoint of PK comparison (bioavailability [BA] evaluation) between ASP8273 Capsules and ASP8273 Capsules A, data from approximately 15 subjects are sufficient for the evaluation.
Therefore, if PK data of approximately 15 subjects included in BA evaluation are obtained and the sponsor judges that further acquisition of PK data is not necessary, the single-dose period will not be conducted in subjects who are enrolled thereafter (subjects not included in BA evaluation).
Subjects will continue to receive treatment with ASP8273 until they meet the discontinuation criteria.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan
- Site: 5
-
Hiroshima, Japan
- Site: 9
-
Hyogo, Japan
- Site: 8
-
Kanagawa, Japan
- Site: 7
-
Miyagi, Japan
- Site: 11
-
Miyagi, Japan
- Site: 1
-
Nagoya, Japan
- Site: 10
-
Okayama, Japan
- Site: 4
-
Osaka, Japan
- Site: 3
-
Osaka, Japan
- Site: 6
-
Tokyo, Japan
- Site: 2
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- Patients with a histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC.
- Patients confirmed to have the deletion of exon 19 (del ex19), L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients at the study site who are documented to have any of the above-stated EGFR activating mutations can be enrolled in the study).
- Patients with a life expectancy ≥ 12 weeks based on the principal investigator's/subinvestigator's judgment.
Patients who meet all of the following requirements for laboratory tests within 7 days before enrollment. When 2 or more test results for a single parameter are found within the specified period, the last data before enrollment should be used for assessment.
- Neutrophil count: ≥ 1,500/mm3
- Platelet count: ≥ 75,000/mm3
- Hemoglobin: ≥ 9 g/dL
- Serum creatinine: < 1.5 mg/dL
- Total bilirubin (TBL): < 1.5 × the upper limit of normal (ULN) at the site (this does not apply to patients with Gilbert syndrome)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): < 2.5 ×the ULN at the site
Patients who meet all the following requirements for prior treatment for NSCLC:
- Patients who have not received previous treatment with EGFR-TKIs*1 *1: Erlotinib, gefitinib, afatinib, and EGFR-TKIs under clinical investigation (e.g.,neratinib, dacomitinib). EGFR-TKIs that can inhibit EGFR with the T790Mmutation (e.g., ASP8273, CO-1686, AZD9291) are also included.
- Patients who have not received more than one regimen of previous drug treatment (however, this does not include preoperative or postoperative therapies used within at least a 6-month interval after the last dose of the treatment).
- Patients who have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Exclusion Criteria:
- Patients with persistent clinical evidence of previous antitumor treatment-related toxicity ≥ Grade 2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCI CTCAE v4.0 - JCOG) (except alopecia).
- Patients with a history of or concurrent interstitial lung disease.
- Patients who have received previous treatment with intended antitumor effects or treatment with another investigational drug/medical device within 14 days before the start of the study treatment.
- Patients who have received transfusion or hematopoietic growth factor therapy within 14 days prior to the start of the study treatment.
- Patients who have received oral or intravenous corticosteroids within 7 days prior to the start of the study treatment (except to treat or prevent an allergic reaction).
- Patients who are scheduled to undergo a surgical procedure during the course of the study or the patient still has an unhealed wound after previous surgery.
- Patients with a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (anti-HCV).
- Patients with a known history of a positive test for human immunodeficiency virus (HIV) infection.
- Patients with symptomatic central nervous system (CNS) lesions.
- Patients with a known history of serious drug hypersensitivity.
- Patients with evidence of active infection requiring systemic drug therapy within 14 days prior to the start of the study treatment.
- Patients who have received strong CYP3A inhibitors within 9 days prior to the start of the study treatment (for itraconazole, within 14 days prior to the start of the study treatment).
- Patients who have received moderate CYP3A inhibitors within 9 days prior to the start of the study treatment (only for subjects included in BA evaluation).
- Patients who have received strong or moderate CYP3A inducers within 14 days prior to the start of the study treatment (only for subjects included in BA evaluation).
- Patients with prolongation of the QTc interval (male: ≥ 451 ms, female: ≥ 471 ms) on the 12-lead electrocardiogram (ECG) in the screening period.
- Patients with cardiac arrhythmias requiring treatment.
- Patients with Class 3 or 4 New York Heart Association (NYHA) congestive heart failure.
- Patients with a history of acute coronary syndrome, myocardial infarction, or cerebrovascular accident within 6 months prior to enrollment.
- Patients with a history of or concurrent active peptic ulcer disease or gastrointestinal bleeding within 3 months prior to enrollment.
- Patients with corneal disease ≥ Grade 2.
- Patients with difficulty to take oral medication, or any gastrointestinal malfunction or inflammatory bowel disease that is considered to affect drug absorption.
- Patients with active multiple cancers (simultaneous multiple cancers).
- Patients with other conditions ineligible for participation in the study based on the principal investigator's/sub-investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP8273 group
Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
|
oral
oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessed by AEs
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Laboratory tests
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Vital signs
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Percutaneous oxygen saturation (SpO2)
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Body weight
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by 12-lead ECG
Time Frame: Up to 18 months
|
ECG: Electrocardiogram
|
Up to 18 months
|
Safety assessed by Ophthalmologic examination
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Chest X-ray examination
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by Chest computed tomography (CT) examination
Time Frame: Up to 18 months
|
Up to 18 months
|
|
Safety assessed by ECOG Performance Status
Time Frame: Up to 18 months
|
Up to 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: Up to 18 months
|
The overall response rate is defined as the proportion of subjects whose best overall response is rated as Complete response (CR) or Partial Response (PR)among all analyzed subjects
|
Up to 18 months
|
Disease control rate
Time Frame: Up to 18 months
|
The disease control rate is defined as the proportion of subjects whose best overall response is rated as Complete response (CR), Partial Response (PR), or Stable disease (SD) among all analyzed subjects
|
Up to 18 months
|
Plasma concentrations of unchanged ASP8273
Time Frame: Up to Day1 of Cycle 3
|
Up to Day1 of Cycle 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2015
Primary Completion (Actual)
June 9, 2017
Study Completion (Actual)
June 9, 2017
Study Registration Dates
First Submitted
June 25, 2015
First Submitted That Met QC Criteria
July 15, 2015
First Posted (Estimate)
July 17, 2015
Study Record Updates
Last Update Posted (Actual)
October 23, 2018
Last Update Submitted That Met QC Criteria
October 22, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Naquotinib
Other Study ID Numbers
- 8273-CL-0202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Sun Yat-sen UniversityRecruitingNon-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline MutationsChina
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
Yonsei UniversityUnknownCompletely Resected NSCLC With Common EGFR MutationsKorea, Republic of
-
Blueprint Medicines CorporationActive, not recruitingNeoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditionsUnited States, Canada, Korea, Republic of, Japan, Taiwan
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, Italy, Korea, Republic of, Canada, France, Australia, Germany, United Kingdom, Hong Kong, Turkey
-
PfizerCompletedNon-small Cell Lung Cancer With EGFR-Activating MutationsItaly, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
-
Fujian Cancer HospitalNot yet recruitingNon-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Clinical Trials on ASP8273 Capsules
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Astellas Pharma IncTerminatedNon-small Cell Lung CancerJapan, Korea, Republic of, Taiwan
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Natural Science Foundation of ChinaRecruiting
-
Caelus Pharmaceuticals BVCompleted